HIV antiretroviral — sunlenca brand, capsid inhibitor used to treat and prevent HIV-1
Uganda reports HIV prevalence stable at 5.9% with 1.496 million adults living with HIV; 85.3% know their status, 99.1% on treatment, 96.5% virally suppressed. In MENA, lenacapavir's global rollout shows affordability gaps and uneven access; six generic manufacturers will produce cheaper versions, but many countries remain excluded, raising concerns over reach of the prevention option.